Burning Rock Biotech Limited Company Analysis & Research
Burning Rock Biotech is a precision oncology company focused on next-generation sequencing (NGS) technology applications for cancer diagnosis and treatment selection. Founded in 2014 and headquartered in Guangzhou, China, the company is the market leader in NGS-based cancer therapy selection testing in China with three primary business segments: central laboratory testing, in-hospital diagnostic services, and pharmaceutical research services.
The company differentiates through proprietary NGS assays including OncoScreen, OncoCompass, and CanCatch platforms that enable both therapy selection and early cancer detection. Strategic partnerships with major pharmaceutical companies including AstraZeneca, Bayer, and Johnson & Johnson strengthen competitive positioning in companion diagnostics and clinical trial biomarker detection services.
Company Overview
Founded: 2014. Headquarters: Guangzhou, China. Revenue: RMB128.6M (Q3 2024). Employees: 1001-5000. Ticker: BNR (NASDAQ).
Industry
Biotechnology - Precision Oncology Diagnostics
Cyborg Score: 6/10 — Solid
Disciplined NGS oncology diagnostics player with dominant China position and early detection potential, but execution and revenue expansion require close monitoring.
Burning Rock holds market leadership in China's NGS-based cancer testing market with strong regulatory recognition, including NMPA breakthrough designation for early cancer detection. However, revenue growth remains modest (0.8% YoY in Q3 2024), reflecting market maturation and business model transition challenges from central lab to in-hospital testing.
Key Strategic Insights for Burning Rock Biotech Limited
- Market leader in NGS-based cancer therapy selection in China, commanding largest patient test volume
- Expanding in-hospital diagnostic business (17% YoY growth in Q3 2024) while managing central lab transition
- Strong pharma partnerships driving companion diagnostics approvals and clinical trial collaboration opportunities
- Clinical-stage cancer early detection (OverC multi-cancer screening) advancing through clinical validation with regulatory breakthrough designation
Recent Developments
- (October 2024) Companion diagnostic for sunvozertinib approved by NMPA - first co-developed NGS-based CDx for lung cancer post-NMPA guideline
- (September 2024) Active participation in precision oncology conferences showcasing advanced assays and research
- (2025) Continued expansion of pharma partnerships and clinical trial biomarker detection services
- (Q3 2024) Revenue stabilization at RMB128.6M with strategic shift toward higher-margin in-hospital testing
Competitors & Competitive Landscape
- Guardant Health — Liquid biopsy ctDNA testing for cancer detection and monitoring
- Myriad Genetics — In-licensed HGSOC diagnostic with Burning Rock partnership in China
- Foundation Medicine — Tissue-based comprehensive genomic profiling for therapy selection
Burning Rock competes in the precision oncology diagnostics space against international players like Guardant Health and Myriad Genetics (with whom it has in-licensing agreements), as well as domestic Chinese competitors. Competitive advantages stem from dominant market share in China, established pharma relationships, regulatory approvals, and proprietary early detection technology platforms.
More Company Research
Feintool International Holding AG Race Oncology Limited Omani Qatari Telecommunications Company SAOG (Ooredoo Oman) Bravura Solutions Limited G-III Apparel Group, Ltd. JetBlue Airways Corporation Pinnacle Investment Management Group Limited ALLETE, Inc. Copa Holdings, S.A. Ayala Corporation Hua Xia Bank Co., Limited Vodafone Group Public Limited Company Berkshire Hathaway Inc. Cemtrex, Inc. Velo3D, Inc.Full Company Research Reports
Looking for a more in-depth analysis of Burning Rock Biotech Limited? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.